Libtayo Libtayo

Generic name: Cemiplimab-rwlc

Commercial name: Libtayo

Company: Regeneron 

FDA approval date: 09/28/2018

NMPA approval date: not yet approved

Indications and usage

for the treatment of metastatic cutaneous squamous cell carcinoma

Dosage Form/Route:

350 mg as an intravenous infusion over 30 minutes every 3 weeks.

Mechanism of Action

a type of immunotherapy treatment called a programmed death receptor-1 (PD-1) inhibitor

Adverse Reactions

The most common side effects of Libtayo include fatigue, rash and diarrhea